ANG Lifesciences India Limited (ANG.BO)
- Previous Close
28.42 - Open
28.56 - Bid 28.60 x --
- Ask 28.98 x --
- Day's Range
28.56 - 28.62 - 52 Week Range
21.03 - 46.00 - Volume
2,771 - Avg. Volume
13,917 - Market Cap (intraday)
373.729M - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-10.81 - Earnings Date Aug 12, 2025 - Aug 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 2, 2021
- 1y Target Est
--
ANG Lifesciences India Limited manufactures and sells pharmaceuticals products and formulations in India. The company's products include various therapeutic categories, such as antibiotics, antiviral, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, and beta lactamase inhibitor. It offers finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, prefilled syringes, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, and lotions. The company was incorporated in 2006 and is based in Amritsar, India.
anglifesciences.com433
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ANG.BO
Afficher davantagePerformance Overview: ANG.BO
Trailing total returns as of 6/4/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Comparer à: ANG.BO
Sélectionnez cette option pour analyser des sociétés comparables en utilisant des indicateurs de performances clés ; sélectionnez jusqu'à 4 actions.
Statistics: ANG.BO
Afficher davantageValuation Measures
Market Cap
371.12M
Enterprise Value
1.08B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.33
Price/Book (mrq)
0.52
Enterprise Value/Revenue
0.95
Enterprise Value/EBITDA
111.29
Financial Highlights
Profitability and Income Statement
Profit Margin
-12.30%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
1.14B
Net Income Avi to Common (ttm)
-140M
Diluted EPS (ttm)
-10.81
Balance Sheet and Cash Flow
Total Cash (mrq)
39.6M
Total Debt/Equity (mrq)
120.05%
Levered Free Cash Flow (ttm)
--